Advances in molecular biology techniques during the past decades allowed for the
scrutiny of tumor derived biomolecules, including circulating tumor DNA
fragments at an unprecedented level. In case of metastatic tumors, the minimally
invasive liquid biopsy sampling provides great opportunity to simultaneously
detect and monitor genetic aberrations emerging at distinct anatomical sites,
and to identify alterations associated with clonal evolution. Consequently,
several studies have recently interrogated the utility of liquid biopsy in the
analysis of solid tumors, with this approach already being incorporated into the
diagnostic workflow of some diseases. In oncohematology, diffuse large B-cell
lymphoma, Hodgkin lymphoma and multiple myeloma are the most intensively studied
entities in this regard. Based on data previously published by our group and
others, the investigation of circulating tumor DNA in hematology has a potential
to convey invaluable prognostic information prior to treatment, to detect
actionable genetic alterations, to monitor treatment efficacy and minimal
residual disease as well as to identify therapy resistant clones. In this
review, we provide an overview of the potential applications of liquid biopsy
analysis in oncohematology.
Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating
tumor cells and circulating tumor DNA. Cancer Discov. 2014; 4:
Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies
into the management of cancer. Nat Rev Clin Oncol. 2017; 14:
Fan HC, Blumenfeld YJ, Chitkara U, et al. Analysis of the size
distributions of fetal and maternal cell-free DNA by paired-end sequencing. Clin
Chem. 2010; 56: 1279–1286.
Alix-Panabieres C, Pantel K. The circulating tumor cells: liquid
biopsy of cancer. Klin Lab Diagn. 2014: 60–64.
Corcoran RB, Chabner BA. Application of cell-free DNA analysis to
cancer treatment. N Engl J Med. 2018; 379: 1754–1765.
Heitzer E, Haque IS, Roberts CES, et al. Current and future
perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet.
2019; 20: 71–88.
Gremel G, Lee RJ, Girotti MR, et al. Distinct subclonal tumour
responses to therapy revealed by circulating cell-free DNA. Ann Oncol. 2016; 27:
Russo M, Siravegna G, Blaszkowsky LS, et al. Tumor heterogeneity and
lesion-specific response to targeted therapy in colorectal cancer. Cancer
Discov. 2016; 6: 147–153.
Camus V, Jardin F. Cell-free DNA and the monitoring of lymphoma
treatment. Pharmacogenomics 2019; 20: 1271–1282.
Darrah JM, Herrera AF. Updates on circulating tumor DNA assessment
in lymphoma. Curr Hematol Malig Rep. 2018; 13: 348–355.
Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA
analysis in patients with cancer: American Society of Clinical Oncology and
College of American Pathologists Joint Review. J Clin Oncol. 2018; 36:
Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating
tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6:
Kilgour E, Rothwell DG, Brady G, et al. Liquid biopsy-based
biomarkers of treatment response and resistance. Cancer Cell 2020; 37:
Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet
digital PCR system for absolute quantitation of DNA copy number. Anal Chem.
2011; 83: 8604–8610.
Alcaide M, Yu S, Bushell K, et al. Multiplex droplet digital PCR
quantification of recurrent somatic mutations in diffuse large B-cell and
follicular lymphoma. Clin Chem. 2016; 62: 1238–1247.
Camus V, Sarafan-Vasseur N, Bohers E, et al. Digital PCR for
quantification of recurrent and potentially actionable somatic mutations in
circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk
Lymphoma 2016; 57: 2171–2179.
Scherer F, Kurtz DM, Diehn M, et al. High-throughput sequencing for
noninvasive disease detection in hematologic malignancies. Blood 2017; 130:
Malapelle U, Sirera R, Jantus-Lewintre E, et al. Profile of the
Roche cobas(R) EGFR mutation test v2 for non-small cell lung cancer. Expert Rev
Mol Diagn. 2017; 17: 209–215.
Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a
sensitive and specific blood test for colorectal cancer. BMC Med. 2011; 9:
Melani C, Wilson WH, and Roschewski M Liquid biopsy in non-Hodgkin’s
lymphoma. Hematol Oncol. 2019; 37 Suppl 1: 70–74.
Roschewski M, Staudt LM, Wilson WH. Dynamic monitoring of
circulating tumor DNA in non-Hodgkin lymphoma. Blood 2016; 127:
Kurtz DM. Prognostication with circulating tumor DNA: is it ready
for prime time? Hematology Am Soc Hematol Educ Program 2019; 2019:
Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of
diffuse large B-cell lymphoma by immunoglobulin high- throughput sequencing.
Blood 2015; 125: 3679–3687.
Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA
and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a
correlative biomarker study. Lancet Oncol. 2015; 16: 541–549.
Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes
and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
Sci Transl Med. 2016; 8: 364ra155.
Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell
lymphoma genotyping on the liquid biopsy. Blood 2017; 129:
Jin MC, Kurtz DM, Esfahani MS, et al. Noninvasive detection of
clinically relevant copy number alterations in diffuse large B-cell lymphoma.
Journal of Clinical Oncology 2017; 35: 7507–7507.
Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat
with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood 2016;
Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA
measurements as early outcome predictors in diffuse large B-cell lymphoma. J
Clin Oncol. 2018; 36: 2845–2853.
Sworder B, Kurtz DM, Macaulay C, et al. Circulating DNA for
molecular response prediction, characterization of resistance mechanisms and
quantification of CAR T-cells during axicabtagene ciloleucel therapy. Blood
2019; 134: 550–550.
van Oers MH, Tonnissen E, Van Glabbeke M, et al. BCL-2/IgH
polymerase chain reaction status at the end of induction treatment is not
predictive for progression-free survival in relapsed/resistant follicular
lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup
study. J Clin Oncol. 2010; 28: 2246–2252.
Roulland S, Kelly RS, Morgado E, et al. t(14;18) translocation: A
predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014; 32:
Rambaldi A, Carlotti E, Oldani E, et al. Quantitative PCR of bone
marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term
outcome in follicular non-Hodgkin lymphoma. Blood 2005; 105:
Mandigers CM, Meijerink JP, Mensink EJ, et al. Lack of correlation
between numbers of circulating t(14;18)-positive cells and response to
first-line treatment in follicular lymphoma. Blood 2001; 98:
Lambrechts AC, Hupkes PE, Dorssers LC, et al. Clinical significance
of t(14; 18)-positive cells in the circulation of patients with stage III or IV
follicular non-Hodgkin’s lymphoma during first remission. J Clin Oncol. 1994;
Gribben JG, Neuberg D, Barber M, et al. Detection of residual
lymphoma cells by polymerase chain reaction in peripheral blood is significantly
less predictive for relapse than detection in bone marrow. Blood 1994; 83:
Sarkozy C, Huet S, Carlton VE, et al. The prognostic value of clonal
heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ
sequences at diagnosis in patients with follicular lymphoma. Oncotarget. 2017;
Delfau-Larue MH, van der Gucht A, Dupuis J, et al. Total metabolic
tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value
in follicular lymphoma. Blood Adv. 2018; 2: 807–816.
Bodor C, Grossmann V, Popov N, et al. EZH2 mutations are frequent
and represent an early event in follicular lymphoma. Blood 2013; 122:
Okosun J, Bodor C, Wang J, et al. Integrated genomic analysis
identifies recurrent mutations and evolution patterns driving the initiation and
progression of follicular lymphoma. Nat Genet. 2014; 46:
Bátai B, Lévai D, Gaál-Weisinger J, et al. New perspective in the
personalized medicine of follicular lymphoma – Targeting the EZH2 histon
methyltransferase. Hematológia−Transzfuziológia 2018; 51:
FDA, FDA granted accelerated approval to tazemetostat for follicular
Morschhauser F, Tilly H, Chaidos A, et al. Phase 2 multicenter study
of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory
follicular lymphoma. Blood 2019; 134: 123–123.
McDonald A, Thomas E, Daigle S, et al. Updated report on
identification of molecular predictors of tazemetostat response in an ongoing
NHL phase 2 study. Blood 2018; 132: 4097–4097.
Nagy A, Batai B, Balogh A, et al. Quantitative analysis and
monitoring of EZH2 mutations using liquid biopsy in follicular lymphoma. Genes
(Basel). 2020; 11.
Fontanilles M, Marguet F, Bohers E, et al. Non-invasive detection of
somatic mutations using next-generation sequencing in primary central nervous
system lymphoma. Oncotarget. 2017; 8: 48157–48168.
Hattori K, Sakata-Yanagimoto M, Suehara Y, et al. Clinical
significance of disease-specific MYD88 mutations in circulating DNA in primary
central nervous system lymphoma. Cancer Sci. 2018; 109:
Watanabe J, Natsumeda M, Kanemaru Y, et al. Comparison of
circulating tumor DNA between body fluids in patients with primary central
nervous system lymphoma. Leuk Lymphoma 2019; 60: 3587–3589.
Zorofchian S, Lu G, Zhu JJ, et al. Detection of the MYD88 p.L265P
mutation in the CSF of a patient with secondary central nervous system lymphoma.
Front Oncol. 2018; 8: 382.
Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, et al. MYD88 p.(L265P)
detection on cell-free DNA in liquid biopsies of patients with primary central
nervous system lymphoma. Br J Haematol. 2019; 185: 974–977.
Hickmann AK, Frick M, Hadaschik D, et al. Molecular tumor analysis
and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA
in patients with central nervous system lymphomas. BMC Cancer. 2019; 19:
Bobillo S, Crespo M, Escudero L, et al. Cell free circulating tumor
DNA in cerebrospinal fluid detects and monitors central nervous system
involvement of B-cell lymphomas. Haematologica 2020.
Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an
ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood
2019; 133: 436–445.
Pott C, Schrader C, Gesk S, et al. Quantitative assessment of
molecular remission after high-dose therapy with autologous stem cell
transplantation predicts long-term remission in mantle cell lymphoma. Blood
2006; 107: 2271–2278.
Cheminant M, Derrieux C, Touzart A, et al. Minimal residual disease
monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA
study. Haematologica 2016; 101: 336–345.
Roschewski MJ, Melani CJ, Pittaluga S, et al. Circulating tumor DNA
to predict timing of relapse in mantle cell lymphoma. Journal of Clinical
Oncology 2018; 36: 7576–7576.
Lakhotia R, Melani C, Pittaluga S, et al. Circulating tumor DNA
dynamics during therapy predict outcomes in mantle cell lymphoma. Blood 2018;
Agarwal R, Chan YC, Tam CS, et al. Dynamic molecular monitoring
reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax
in mantle cell lymphoma. Nat Med. 2019; 25: 119–129.
Pizzi M, Margolskee E, Inghirami G. Pathogenesis of peripheral
T-cell lymphoma. Annu Rev Pathol. 2018; 13: 293–320.
Sakata-Yanagimoto M, Nakamoto-Matsubara R, Komori D, et al.
Detection of the circulating tumor DNAs in angioimmunoblastic T-cell lymphoma.
Ann Hematol. 2017; 96: 1471–1475.
Sun P, Chen C, Xia Y, et al. Mutation profiling of malignant
lymphoma by next-generation sequencing of circulating cell-free DNA. J Cancer.
2019; 10: 323–331.
Melani C, Pittaluga S, Yee L, et al. Next-generation sequencing
based monitoring of circulating-tumor DNA in untreated peripheral T-cell
lymphoma. Blood 2017; 130: 2728–2728.
Borchmann S, Engert A. The genetics of Hodgkin lymphoma: an overview
and clinical implications. Curr Opin Oncol. 2017; 29: 307–314.
Jin MC, Schroers-Martin JG, Kurtz DM, et al. Noninvasive genotyping
and monitoring of classical Hodgkin lymphoma. Blood 2018; 132:
Hohaus S, Giachelia M, Massini G, et al. Cell-free circulating DNA
in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol. 2009; 20:
Vandenberghe P, Wlodarska I, Tousseyn T, et al. Non-invasive
detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and
advanced stage Hodgkin’s lymphoma by sequencing of circulating cell-free DNA: a
technical proof-of-principle study. Lancet Haematol. 2015; 2:
Camus V, Stamatoullas A, Mareschal S, et al. Detection and
prognostic value of recurrent exportin 1 mutations in tumor and cell-free
circulating DNA of patients with classical Hodgkin lymphoma. Haematologica 2016;
Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA
reveals genetics, clonal evolution, and residual disease in classical Hodgkin
lymphoma. Blood 2018; 131: 2413–2425.
Herrera AF, Kim HT, Kong KA, et al. Next-generation sequencing-based
detection of circulating tumour DNA After allogeneic stem cell transplantation
for lymphoma. Br J Haematol. 2016; 175: 841–850.
Oki Y, Neelapu SS, Fanale M, et al. Detection of classical Hodgkin
lymphoma specific sequence in peripheral blood using a next-generation
sequencing approach. Br J Haematol. 2015; 169: 689–693.
Pugh TJ. Circulating tumour DNA for detecting minimal residual
disease in multiple myeloma. Semin Hematol. 2018; 55: 38–40.
Waldschmidt JM, Anand P, Knoechel B, et al. Comprehensive
characterization of circulating and bone marrow-derived multiple myeloma cells
at minimal residual disease. Semin Hematol. 2018; 55: 33–37.
Mithraprabhu S, Khong T, Ramachandran M, et al. Circulating tumour
DNA analysis demonstrates spatial mutational heterogeneity that coincides with
disease relapse in myeloma. Leukemia 2017; 31: 1695–1705.
Gerber B, Manzoni M, Spina V, et al. Circulating tumor DNA as a
liquid biopsy in plasma cell dyscrasias. Haematologica 2018; 103:
Kis O, Kaedbey R, Chow S, et al. Circulating tumour DNA sequence
analysis as an alternative to multiple myeloma bone marrow aspirates. Nat
Commun. 2017; 8: 15086.
Mithraprabhu S, Morley R, Khong T, et al. Monitoring tumour burden
and therapeutic response through analysis of circulating tumour DNA and
extracellular RNA in multiple myeloma patients. Leukemia 2019; 33:
Biancon G, Gimondi S, Vendramin A, et al. Noninvasive molecular
monitoring in multiple myeloma patients using cell-free tumor DNA: A pilot
study. J Mol Diagn. 2018; 20: 859–870.
Mazzotti C, Buisson L, Maheo S, et al. Myeloma MRD by deep
sequencing from circulating tumor DNA does not correlate with results obtained
in the bone marrow. Blood Adv. 2018; 2: 2811–2813.
Oberle A, Brandt A, Voigtlaender M, et al. Monitoring multiple
myeloma by next-generation sequencing of V(D)J rearrangements from circulating
myeloma cells and cell-free myeloma DNA. Haematologica 2017; 102:
Rustad EH, Coward E, Skytoen ER, et al. Monitoring multiple myeloma
by quantification of recurrent mutations in serum. Haematologica 2017; 102:
Rajeev Krishnan S, De Rubis G, Suen H, et al. A liquid biopsy to
detect multidrug resistance and disease burden in multiple myeloma. Blood Cancer
J. 2020; 10: 37.
Manier S, Park J, Capelletti M, et al. Whole-exome sequencing of
cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun. 2018;
Yeh P, Hunter T, Sinha D, et al. Circulating tumour DNA reflects
treatment response and clonal evolution in chronic lymphocytic leukaemia. Nat
Commun. 2017; 8: 14756.
Kiss R, Alpar D, Gango A, et al. Spatial clonal evolution leading to
ibrutinib resistance and disease progression in chronic lymphocytic leukemia.
Haematologica 2019; 104: e38–e41.
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus
chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med.
2017; 377: 454–464.
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic
classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374:
Klco JM, Miller CA, Griffith M, et al. Association between mutation
clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA
2015; 314: 811–822.
Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of
AML in adults: 2017 ELN recommendations from an international expert panel.
Blood 2017; 129: 424–447.
Krizsán S, Dénes Z, Gángó A, et al. Visszatérő genetikai eltérések
vizsgálata akut myeloid leukémiában az új célzott terápiák tükrében.
Hematológia–Transzfuziológia 2019; 52: 96–105.
Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable
residual disease in AML: a consensus document from the European LeukemiaNet MRD
Working Party. Blood 2018; 131: 1275–1291.
Vasioukhin V, Anker P, Maurice P, et al. Point mutations of the
N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or
acute myelogenous leukaemia. Br J Haematol. 1994; 86: 774–779.
Quan J, Gao YJ, Yang ZL, et al. Quantitative detection of
circulating nucleophosmin mutations DNA in the plasma of patients with acute
myeloid leukemia. Int J Med Sci. 2015; 12: 17–22.
Ma W, Kantarjian H, Zhang X, et al. Detection of nucleophosmin gene
mutations in plasma from patients with acute myeloid leukemia: clinical
significance and implications. Cancer Biomark. 2009; 5: 51–58.
Nakamura S, Yokoyama K, Shimizu E, et al. Prognostic impact of
circulating tumor DNA status post-allogeneic hematopoietic stem cell
transplantation in AML and MDS. Blood 2019; 133: 2682–2695.
Suzuki Y, Tomita A, Nakamura F, et al. Peripheral blood cell-free
DNA is an alternative tumor DNA source reflecting disease status in
myelodysplastic syndromes. Cancer Sci. 2016; 107: 1329–1337.
Yeh P, Dickinson M, Ftouni S, et al. Molecular disease monitoring
using circulating tumor DNA in myelodysplastic syndromes. Blood 2017; 129:
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020
recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34:
Choi MY, Kato S, Wang HY, et al. JAK2 V617F mutation in plasma
cell-free DNA preceding clinically overt myelofibrosis: Implications for early
diagnosis. Cancer Biol Ther. 2018; 19: 664–668.